Table 5.
Comparison on CIR of cancer between newly-diagnosed and prevalent T2DM patients
| Male | Female | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of T2DM | Person-years (PY) of follow-up | No. of cancer cases | CIR# | No. of T2DM | Person-years (PY) of follow-up | No. of cancer cases | CIR | No. of T2DM | Person-years (PY) of follow-up | No. of cancer cases | CIR | |
| Newly-diagnosed D2TM patients | 3899 | 12877 | 80 | 621.26 | 4875 | 16251 | 64 | 393.82 | 8774 | 29128 | 144 | 494.37 |
| Prevalent D2TM patients | 12267 | 47005 | 492 | 1046.70 | 15338 | 60054 | 569 | 947.48 | 27605 | 107059 | 1061 | 991.04 |
| U-test | U = 5.06, P < 0.05 | U = 8.75, P < 0.05 | U = 6.44, P < 0.05 | |||||||||
#CIR: crude incidence rate (per 100000 person years)